Diagnostic Usefulness of p16/CDKN2A FISH in Distinguishing Between Sarcomatoid Mesothelioma and Fibrous Pleuritis

Dept of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, 477-96 Owada-Shinden, Yachiyo, Chiba 276-8524, Japan.
American Journal of Clinical Pathology (Impact Factor: 2.51). 01/2013; 139(1):39-46. DOI: 10.1309/AJCPT94JVWIHBKRD
Source: PubMed


The distinction between sarcomatoid mesothelioma and fibrous pleuritis is difficult based on histology, especially when the amount of tumor tissue examined via biopsy is small and immunohistochemical examination is inconclusive. We studied the usefulness of deletion of p16 with fluorescence in situ hybridization (FISH) and p16 hypermethylation with polymerase chain reaction for the diagnosis and prognosis of malignant pleural mesothelioma (MPM). We analyzed 50 MPMs, including 22 sarcomatoid mesothelioma cases and 10 fibrous pleuritis cases. We set the cutoff value of homozygous deletion pattern as 14.4% based on FISH signaling patterns using samples of fibrous pleuritis. The percentage of homozygous deletion pattern was higher than 14.4% in 55.6% of the epithelioid mesotheliomas (10/18) and in all of the sarcomatoid mesotheliomas (22/22). Methylation of p16 was observed in 7 (20.6%) of 34 informative cases. p16 FISH analysis can be a reliable test for distinguishing between sarcomatoid mesothelioma and fibrous pleuritis and a prognostic factor for MPM.

Download full-text


Available from: Hideaki Shimada,
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant mesothelioma (MM) is an aggressive tumor arising primarily from the pleural or peritoneal cavities. It develops by asbestos exposure after a long latency, which is characterized by insidious growth and clinical presentation at an advanced stage of disease. MM is highly refractory to conventional therapies even with a combination of aggressive surgical intervention and multimodality strategies, with cure remaining elusive. Molecular genetic analysis has revealed several key genetic alterations which are responsible for the development and progression of MM. The CDKN2A/ ARF, NF2, and BAP1 genes are the most frequently mutated tumor suppressor genes detected in MM cells; the alterations of the latter two are relatively characteristic of MM. Merlin, which is encoded by NF2, regulates multiple cell signaling cascades including the Hippo and mTOR pathways which regulate cell proliferation and growth. BAP1 is involved in histone modification and its inactivation induces the disturbance of global gene expression profiling. The discovery of a new familial cancer syndrome with germline mutation of BAP1 also indicates the importance of genetic factors in MM susceptibility. Meanwhile, although frequent expression and functional activations of oncogene products such as receptor tyrosine kinases are observed in MM cells, activating mutations of these genes are rare. With further comprehensive genome analyses, new genetic and epigenetic alterations in MM cells are expected to be revealed more precisely, and the new knowledge based on them will be applied for developing new diagnostic tools and new target therapies against MMs.
    Carcinogenesis 05/2013; 34(7). DOI:10.1093/carcin/bgt166 · 5.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Distinguishing between malignant mesothelioma and reactive mesothelial hyperplasia is often inestimable, but may be a challenging gauntlet for pathologists. A 62-year-old man underwent appendectomy after the identification of a peritoneal mass and the histological examination showed mesothelial proliferation along the appendix surface with no clear images of infiltration. After a few months the patient developed mediastinal and supraclavicular lymphadenopathies, and a nodal biopsy showed mesothelial cell proliferation invading lymphatic sinuses, consistent with the cells seen in the abdominal cavity. Since overt morphologic criteria for malignancy were lacking and reactive mesothelial cell deposits have been documented in lymph nodes, a molecular investigation of the CDKN2A (henceforth simply p16) gene status via fluorescence in situ hybridization was performed, which showed homozygous deletion in 100% tumor cells. These data ruled out the hypothesis of reactive mesothelial cells inclusion in lymph nodes, thus confirming the diagnosis of epithelioid malignant mesothelioma.
    International Journal of Surgical Pathology 01/2014; 22(6). DOI:10.1177/1066896913520037 · 0.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pleuraerkrankungen sind mit einer jährlichen Inzidenz von 300–400/100.000 Einwohnern ein häufiger klinischer Befund. Im Untersuchungsgut der Pathologie sind primäre Pleuraerkrankungen eher selten. Wesentlich häufiger ist eine sekundäre Mitbeteiligung der Pleura bei entzündlichen oder neoplastischen pulmonalen Erkrankungen in Form der Pleuritis, der lokalisierten und diffusen Pleurafibrose, der Pleuraschwarte, des Pleuraempyems und insbesondere der Pleurakarzinosen. Eine besondere Herausforderung stellt die Abgrenzung reaktiver Mesothelzellhyperplasien von Frühphasen maligner epitheloider Pleuramesotheliome dar. Die differentialdiagnostische Unterscheidung primärer Pleuratumoren von Metastasen erfordert ergänzende immunhistochemische und z. T. molekularpathologische Untersuchungen. Für die ätiologische Zuordnung benigner und maligner Pleuraerkrankungen sind Anamnese sowie klinische und radiologische Befunde entscheidend. Für die Tumorsicherung muss dem Pathologen ausreichend Untersuchungsmaterial zur Verfügung gestellt werden. Benigne und maligne Pleuraerkrankungen als asbestassoziierte Erkrankungen gewinnen besondere Bedeutung unter versicherungsmedizinischen Aspekten einer Berufskrankheit.
    Der Pneumologe 02/2014; 12(1):44-51. DOI:10.1007/s10405-014-0809-5
Show more